Morepen Labs.

Which are the latest news on Morepen Labs.?

Why is Morepen Laboratories Ltd falling/rising?

As of 05-Sep, Morepen Laboratories Ltd's stock is experiencing a short-term decline of 3.15% after a recent trend reversal, but it has shown strong long-term performance with a 64.28% increase over the past month and a year-to-date return of 176.84%. Despite the current drop, robust investor interest and positive long-term trends suggest potential for recovery.

As of 05-Sep, Morepen Laboratories Ltd's stock price is currently falling, with a change of -3.7, representing a decrease of 3.15%. This decline follows a recent trend reversal after two consecutive days of gains. The stock touched an intraday low of Rs 112.7, which is a 4% drop from its previous levels. Additionally, the stock underperformed its sector by 2.7% today.<BR><BR>Despite this short-term decline, Morepen Laboratories has shown strong performance over longer periods. The stock has increased by 64.28% over the past month and has a remarkable year-to-date return of 176.84%. It has also achieved a new 52-week high of Rs 118.85 earlier today, indicating strong upward momentum prior to the current drop.<BR><BR>Investor participation remains robust, with a delivery volume of 94.22 lacs on September 3, which is a 2.74% increase compared to the 5-day average. Furthermore, the stock is trading above its moving averages across various time frames, suggesting a generally positive trend in the longer term.<BR><BR>In summary, while Morepen Laboratories Ltd is experiencing a short-term decline in stock price, its strong performance metrics and investor interest indicate that the fundamentals remain solid, which could support recovery in the near future.

Who are in the management team of Morepen Labs.?

The management team of Morepen Labs includes Sushil Suri (Chairman & Managing Director), Manoj Joshi, Bhupender Raj Wadhwa, Sukhcharan Singh, Praveen Kumar Dutt, and Savita (all Non-Executive & Independent Directors), along with Vipul Kumar Srivatava (Company Secretary & Compliance Officer) and Sanjay Suri (Whole-time Director). This team is responsible for the company's strategic direction and governance.

The management team of Morepen Labs includes the following members:<BR><BR>1. **Sushil Suri** - Chairman & Managing Director<BR>2. **Manoj Joshi** - Non-Executive & Independent Director<BR>3. **Bhupender Raj Wadhwa** - Non-Executive & Independent Director<BR>4. **Sukhcharan Singh** - Non-Executive & Independent Director<BR>5. **Vipul Kumar Srivatava** - Company Secretary & Compliance Officer<BR>6. **Sanjay Suri** - Whole-time Director<BR>7. **Praveen Kumar Dutt** - Non-Executive & Independent Director<BR>8. **Savita** - Non-Executive & Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance. If you need more specific information about any individual or their roles, feel free to ask!

What does Morepen Labs. do?

Morepen Laboratories Limited is an Indian pharmaceutical company specializing in the Pharmaceuticals & Biotechnology sector, with recent net sales of ₹570 Cr and a net profit of ₹56 Cr as of June 2026. It has a market capitalization of ₹5,651 Cr and key metrics include a P/E ratio of 50.00 and a dividend yield of 0.19%.

Overview: <BR>Morepen Laboratories Limited is an India-based pharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap.<BR><BR>History: <BR>Morepen Laboratories Ltd was incorporated in an unspecified year and has maintained its status as a pharmaceutical company. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 570 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 56 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 5,651 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 50.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.19% <BR>Debt Equity: 0.09 <BR>Return on Equity: 5.75% <BR>Price to Book: 4.67<BR><BR>Contact Details: <BR>Address: Morepen Village, Nalagarh Road Near Baddi Solan Himachal Pradesh : 173205 <BR>Tel: 91-01795-276201-03 <BR>Email: investors@morepen.com <BR>Website: http://www.morepen.com

Who are the peers of the Morepen Labs.?

Peers of Morepen Labs include Bliss GVS Pharma, Innova Captab, Orchid Pharma, IOL Chemicals, FDC, Guj. Themis Bio., RPG LifeScience, Unichem Labs, Gufic BioScience, and Aarti Drugs. Morepen Labs has a positive 1-year return of 129.51%, while Bliss GVS Pharma leads with 295.64%, and FDC shows the lowest return at -26.41%.

Peers: The peers of Morepen Labs. are Bliss GVS Pharma, Innova Captab, Orchid Pharma, IOL Chemicals, FDC, Guj. Themis Bio., RPG LifeScience., Unichem Labs., Gufic BioScience, and Aarti Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Innova Captab and Guj. Themis Bio., while Average management risk is found at Bliss GVS Pharma, Orchid Pharma, Morepen Labs., IOL Chemicals, FDC, RPG LifeScience., Unichem Labs., Gufic BioScience, and Aarti Drugs. Growth ratings show that Good growth is noted at Unichem Labs., while Average growth is seen at Innova Captab and the rest have Below Average growth. Capital Structure is Excellent for Bliss GVS Pharma, Innova Captab, Morepen Labs., IOL Chemicals, FDC, Guj. Themis Bio., RPG LifeScience., while Average is noted for Orchid Pharma, Gufic BioScience, and Aarti Drugs.<BR><BR>Return Snapshot: Bliss GVS Pharma has the highest 1-year return at 295.64%, while FDC has the lowest at -26.41%. Morepen Labs.'s 1-year return of 129.51% is significantly positive compared to FDC. Additionally, FDC and Aarti Drugs have negative six-month returns.

How big is Morepen Labs.?

As of 31st August, Morepen Laboratories Ltd has a market capitalization of 5,651.00 Cr, with recent net sales of 1,950.59 Cr and a net profit of 140.52 Cr. Shareholder's funds are 1,156.23 Cr and total assets amount to 1,778.10 Cr as of March 2025.

As of 31st August, Morepen Laboratories Ltd has a market capitalization of 5,651.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest 4 quarters, Morepen Labs reported Net Sales of 1,950.59 Cr and a Net Profit of 140.52 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 1,156.23 Cr and Total Assets of 1,778.10 Cr.

Are Morepen Laboratories Ltd latest results good or bad?

Morepen Laboratories Ltd's latest Q1 FY27 results are strong, with a 34.07% revenue increase and a 424.65% rise in net profit, indicating a significant turnaround. However, concerns about the sustainability of this growth remain, as historical performance has been modest.

Morepen Laboratories Ltd's latest results for Q1 FY27 are quite impressive and indicate a significant turnaround for the company. Revenue surged by 34.07% year-on-year to ₹570.13 crores, marking the highest quarterly sales figure on record. Additionally, the operating margin expanded sharply to 14.48%, a notable improvement from previous quarters.<BR><BR>The net profit also saw a dramatic increase, rising 424.65% year-on-year to ₹56.40 crores. This reflects not only strong revenue growth but also enhanced operational efficiency. The company's ability to achieve double-digit profitability after a period of subdued performance has garnered attention in the market.<BR><BR>However, while the results are positive, there are some concerns regarding the sustainability of this growth. The company's historical performance has shown modest long-term growth, and questions remain about whether this quarter's results represent a new trend or a temporary spike. The market is currently valuing Morepen at 32x trailing earnings, which is below the industry average, suggesting some skepticism about the sustainability of these results.<BR><BR>In summary, Morepen's latest results are good, showcasing strong revenue and profit growth, but investors should remain cautious and monitor future performance to determine if this positive trend can be sustained.

Should I buy, sell or hold Morepen Laboratories Ltd?

When is the next results date for Morepen Laboratories Ltd?

The next results date for Morepen Laboratories Ltd is August 4, 2026.

The next results date for Morepen Laboratories Ltd is scheduled for August 4, 2026.

How has been the historical performance of Morepen Labs.?

Morepen Labs has shown consistent growth in net sales and profitability, with net sales increasing from 768.54 crore in March 2019 to 1,811.58 crore in March 2025, and profit after tax rising from 28.84 crore to 118.02 crore in the same period. The company's total assets and liabilities also grew significantly, reflecting robust expansion.

Answer:<BR>The historical performance of Morepen Labs shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Morepen Labs has demonstrated significant growth in net sales, increasing from 768.54 crore in March 2019 to 1,811.58 crore in March 2025. The total operating income followed a similar trend, reaching 1,811.58 crore in March 2025, up from 853.07 crore in March 2020. The company's operating profit (PBDIT) also improved, rising to 192.43 crore in March 2025 from 71.19 crore in March 2019. Profit before tax increased to 155.11 crore in March 2025, compared to 29.18 crore in March 2019, while profit after tax reached 118.02 crore in March 2025, up from 28.84 crore in March 2019. The company's total assets grew significantly from 663.46 crore in March 2020 to 1,778.10 crore in March 2025, reflecting a robust expansion. Total liabilities also increased, from 663.46 crore in March 2020 to 1,778.10 crore in March 2025, indicating a rise in borrowings and other obligations. Cash flow from operating activities showed fluctuations, with a net cash inflow of 10 crore in March 2025, following a net outflow in the previous year. Overall, Morepen Labs has shown a strong upward trend in sales and profitability, alongside an increase in total assets and liabilities over the years.

Is Morepen Labs. technically bullish or bearish?

As of November 19, 2025, Morepen Labs is in a bearish trend with moderate strength, supported by bearish MACD and moving averages, while showing mixed signals from KST and underperforming against the Sensex.

As of 19 November 2025, the technical trend for Morepen Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is bearish, and the daily moving averages confirm this bearish outlook. Bollinger Bands are also indicating a bearish trend on both weekly and monthly time frames. The KST shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, indicating some mixed signals. Overall, the Dow Theory supports a mildly bearish view on both weekly and monthly time frames. The stock has underperformed significantly against the Sensex over various periods, further reinforcing the bearish sentiment.

Is Morepen Labs. overvalued or undervalued?

As of November 17, 2025, Morepen Labs is fairly valued with a PE ratio of 33.58, lower than Sun Pharma's 36.69 but higher than Cipla's 22.81, and has a low PEG ratio of 0.00, while underperforming the Sensex with a stock return of -38.87%.

As of 17 November 2025, Morepen Labs has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 33.58, an EV to EBITDA of 19.59, and a Price to Book Value of 2.12. <BR><BR>In comparison with its peers, Morepen Labs' PE ratio is lower than that of Sun Pharma, which stands at 36.69, but higher than Cipla's attractive valuation of 22.81. The PEG ratio for Morepen is notably low at 0.00, indicating potential growth concerns compared to peers like Divi's Lab, which has a PEG of 1.97. Additionally, Morepen Labs has underperformed the Sensex significantly over the past year, with a stock return of -38.87% compared to the Sensex's 9.50%.

Who are the top shareholders of the Morepen Labs.?

The top shareholders of Morepen Labs include Pinfold Overseas Limited with 7.03%, Scope Credits And Financial Services Pvt. Ltd. at 2.84%, and individual investors collectively holding 48.76%. There are also 44 Foreign Institutional Investors with 1.94% and no pledged promoter holdings.

The top shareholders of Morepen Labs include a mix of individual and institutional investors. The largest public shareholder is Pinfold Overseas Limited, holding 7.03%. Among the promoters, Scope Credits And Financial Services Pvt. Ltd. has the highest stake at 2.84%. Additionally, individual investors collectively hold a significant portion of 48.76%. There are also 44 Foreign Institutional Investors (FIIs) with a combined holding of 1.94%, and two mutual fund schemes that hold 0.0%. Notably, there are no pledged promoter holdings.

Has Morepen Labs. declared dividend?

No Dividend History Available